Home

Becton Dickinson (BDX)

180.90
+2.63 (1.48%)
NYSE · Last Trade: Jul 17th, 11:18 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close178.27
Open178.27
Bid176.24
Ask182.45
Day's Range177.10 - 181.04
52 Week Range163.33 - 251.99
Volume3,946,282
Market Cap51.95B
PE Ratio (TTM)35.06
EPS (TTM)5.2
Dividend & Yield4.160 (2.30%)
1 Month Average Volume3,258,367

Chart

About Becton Dickinson (BDX)

Becton Dickinson is a global medical technology company that specializes in the development and manufacture of medical devices, instrument systems, and reagents. The company focuses on improving patient care and advancing healthcare delivery through its diverse product offerings, which include syringes, needles, blood collection systems, and diagnostic tools. With a strong commitment to innovation and quality, Becton Dickinson serves healthcare professionals and institutions around the world, facilitating safe and effective medical procedures and enhancing the overall health and well-being of patients. Read More

News & Press Releases

How Do Investors Really Feel About Becton Dickinson?benzinga.com
Via Benzinga · July 15, 2025
Market Monitor News July 15 BMO (Crypto stocks UP - Waters DOWN)chartmill.com
Calm Before the Storm? Wall Street Holds Its Breath Ahead of Earnings and Inflation Bombshells
Via Chartmill · July 15, 2025
Q1 Rundown: BD (NYSE:BDX) Vs Other Surgical Equipment & Consumables - Diversified Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how surgical equipment & consumables - diversified stocks fared in Q1, starting with BD (NYSE:BDX).
Via StockStory · July 14, 2025
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Monogram Technologies Inc. (Nasdaq - MGRM), Veritex Holdings, Inc. (Nasdaq - VBTX), ESSA Pharma Inc. (Nasdaq - EPIX), Waters Corporation (NYSE - WAT)
BALA CYNWYD, Pa., July 14, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
By Brodsky & Smith LLC · Via GlobeNewswire · July 14, 2025
How Is The Market Feeling About Becton Dickinson?benzinga.com
Via Benzinga · June 4, 2025
Becton's Biosciences And Diagnostics Arm Slated To Join Waters In $17.5 Billion Mergerbenzinga.com
BD to spin off its diagnostics and biosciences business in a $17.5 billion merger with Waters, targeting $345 million in synergies by 2030.
Via Benzinga · July 14, 2025
1 Large-Cap Stock Worth Investigating and 2 to Think Twice About
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.
Via StockStory · July 14, 2025
The Best High Yield Medical Device Stock to Invest $1,000 in Right Nowfool.com
Via The Motley Fool · July 11, 2025
3 of Wall Street’s Favorite Stocks with Mounting Challenges
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Via StockStory · July 11, 2025
1 Cash-Producing Stock Worth Your Attention and 2 to Brush Off
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Via StockStory · June 30, 2025
Becton Dickinson Stock (BDX): Why It's Best To Avoid For Nowbenzinga.com
Becton Dickinson stock (BDX): Signs point toward continued underperformance until early June 2027.
Via Benzinga · June 25, 2025
New Jersey Rep. Thomas Kean Bought Over $4K Worth of Amazon.com Stock: Here's What You Should Knowbenzinga.com
Via Benzinga · June 18, 2025
3 Healthcare Stocks Skating on Thin Ice
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six months, the industry has pulled back by 12.3%. This performance was noticeably worse than the S&P 500’s 1.9% fall.
Via StockStory · June 4, 2025
3 Value Stocks Facing Headwinds
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.
Via StockStory · May 23, 2025
Accenture To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Thursdaybenzinga.com
Via Benzinga · May 22, 2025
6 Analysts Have This To Say About Becton Dickinsonbenzinga.com
Via Benzinga · May 22, 2025
3 Dawdling Stocks with Questionable Fundamentals
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.
Via StockStory · May 15, 2025
BDX Q1 Earnings Call: Missed Revenue Expectations, Margin Expansion, and Strategic U.S. Investments
Medical technology company Becton, Dickinson and Company (NYSE:BDX) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 4.5% year on year to $5.27 billion. On the other hand, the company’s outlook for the full year was close to analysts’ estimates with revenue guided to $21.85 billion at the midpoint. Its non-GAAP profit of $3.35 per share was 2.1% above analysts’ consensus estimates.
Via StockStory · May 14, 2025
Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030benzinga.com
Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states.
Via Benzinga · May 14, 2025
Only Half Of S&P 500 Stocks Joined The Tariff-Relief Rally: Time To Buy The Laggards?benzinga.com
Only about 50% of S&P 500 stocks trade above their 200-day average, signaling narrow breadth even as the index rallies 22% since April.
Via Benzinga · May 14, 2025
3 Profitable Stocks with Questionable Fundamentals
A company with profits isn’t always a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Via StockStory · May 9, 2025
FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversightbenzinga.com
FDA to increase surprise inspections at foreign facilities as U.S. companies pour billions into domestic drug and device manufacturing.
Via Benzinga · May 6, 2025
Block, Becton Dickinson And Pilgrim's Pride Are Among Top 10 Large-Cap Losers Last Week (Apr 28-May 2): Are The Others In Your Portfolio?benzinga.com
Via Benzinga · May 4, 2025
Becton Dickinson Vitals Drop: Analysts 'Have Been Wrong' On This Med Tech Stock For Yearsbenzinga.com
Becton Dickinson receives multiple downgrades as analysts cite weakening organic growth and trimmed price targets following a Q2 update.
Via Benzinga · May 2, 2025
Wall Street Fully Recoups Tariff-Led Losses, Economy Contracts In First Quarter Yet April Payrolls Remain Strong: This Week In Marketsbenzinga.com
Via Benzinga · May 2, 2025